New hope for stem cell transplant patients: drug targets stubborn GvHD
NCT ID NCT01688466
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD), a condition where donor immune cells attack the recipient's body after a stem cell transplant. Participants had GvHD that did not improve with standard treatments. They took pomalidomide capsules daily for up to 6 months, with possible extension. The goal was to see if the drug could safely control the disease and reduce symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.